Ahead of adcomm, FDA backs Rexulti for first approval for agitation associated with Alzheimer’s dementia
A label expansion is likely in the cards for Otsuka and Lundbeck’s drug Rexulti (brexpiprazole) as the FDA said ahead of a Friday adcomm that …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
